Sanofi, in partnership with Regeneron, had been testing the drug’s effects against COVID-19 because the drug is proven to curb inflammation. But the drug didn’t significantly shorten patients’ hospital stays in a study involving 420 people, Sanofi said.
Sanofi said patients were just about as likely to develop severe infections and die while on Kevzara as they were on a placebo.
Sanofi CEO Paul Hudson has said Kevzara was a “long shot” as a treatment against COVID-19, according to Bloomberg.
Regeneron is also testing an antibody drug cocktail it has developed specifically for COVID-19.
More articles on pharmacy:
Mylan recalls 2 drugs after label mix-up
Novartis establishes new sustainability goals
Bayer to acquire vitamin subscription company for $225M
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
